Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrationa
NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrationa